Evgen Pharma plc
("Evgen" or "the
Company" or "the Group")
Positive update on SFX-01 in vitro Glioblastoma (GBM)
studies
Further evidence of SFX-01 activity as
seen at other academic centres
Alderley Park,
UK - 19 February 2024: Evgen
Pharma plc (AIM: EVG), the clinical stage drug development company
developing sulforaphane-based medicines for the treatment of
multiple diseases, announces that the laboratory of Dr Marjolein
Geurts, neuro-oncologist at the Erasmus University Medical Centre
has observed continuing activity of SFX-01 in GBM cells.
The in
vitro studies, which are supported by a grant awarded by the
KWF Dutch Cancer Society for a €1.1m project, are designed to
investigate the activity of SFX-01 in preclinical GBM models. This
work is to be followed by administration of SFX-01 to patients with
GBM in a clinical Investigator Sponsored Study (ISS). The
scientific collaboration, which commenced in October 2023, will run
for three years, generating data continuously throughout the
period.
According to the lead investigator,
Dr Marjolein Geurts,
neuro-oncologist at Erasmus University Medical Center,
"We have seen continued evidence
of biological activity in patient-derived glioblastoma
tissue."
Dr Huw Jones,
CEO of Evgen Pharma said:
"These early
data triangulate with those seen by our other academic
collaborators in Abbruzzo, Italy and Auckland, New Zealand. This is
another major academic group observing these effects in tissue
derived from a different population of GBM patients which gives us
further confidence of SFX-01's potential as a therapeutic option
for glioblastoma, a disease with very high unmet medical
needs which
is devastating for patients and their
carers."
-Ends-
Enquiries
Evgen
Pharma plc
Dr Huw Jones, CEO
Toni Hänninen, CFO
Dr Helen Kuhlman, CBO
|
+44 207 457 2020
enquiries@evgen.com
|
Cavendish Capital Markets (NOMAD and
Broker) Geoff Nash /
Teddy Whiley (Corporate Finance)
Nigel Birks (ECM)
|
+44 20 7220
0500
|
Instinctif Partners
Melanie Toyne-Sewell / Jack
Kincade
|
+44 207 457 2020
Evgen@Instinctif.com
|
About Evgen
Pharma plc
Evgen Pharma is a clinical stage drug
development company developing sulforaphane based medicines for the
treatment of multiple diseases. The Company's core technology is
Sulforadex®, a method for synthesising and stabilising the highly
biologically active compound sulforaphane and novel proprietary
analogues based on sulforaphane.
The Company's lead asset, SFX-01, is a patented
composition of synthetic sulforaphane and alpha-cyclodextrin and
has undergone clinical trials for oestrogen-positive (ER+)
metastatic breast cancer and recently a Phase 1b study of the
Company's new enteric coated tablet formulation. The FDA has
granted Orphan Drug status to SFX-01 in malignant glioma. SFX-01
will be investigated initially in this indication as an
investigator sponsored study in the Netherlands.
The Company also has a wide number of
collaborations with leading academic centres in the UK, Europe and
the US as part of the continuing strategy to build the scientific
data for the compound. Recently, Evgen completed an out-licensing
transaction with Stalicla SA, a Swiss specialist company in
neurodevelopmental disorders, commencing with autism spectrum
disorder. The deal, if successful, will generate milestone payments
of $160.5m and a double-digit royalty on sales.
The Company has its headquarters and registered
office at Alderley Park, Cheshire. It is listed on AIM in London
and trades under the ticker symbol EVG.
For further information, please
visit: www.evgen.com.